<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102752</url>
  </required_header>
  <id_info>
    <org_study_id>TH-CR-301</org_study_id>
    <nct_id>NCT00102752</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer</brief_title>
  <official_title>A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of glufosfamide when administered in&#xD;
      combination with gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study, TH-CR-301, is a Phase 1/2 study that will evaluate the efficacy and safety of&#xD;
      glufosfamide in combination with gemcitabine in advanced solid tumors or in first line&#xD;
      treatment of pancreatic cancer.&#xD;
&#xD;
      Study Hypothesis: Glufosfamide in combination with gemcitabine may provide benefits in&#xD;
      survival to patients with advanced solid tumors or metastatic pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6- and 12- month survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CA-19-9</measure>
  </secondary_outcome>
  <enrollment>47</enrollment>
  <condition>Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glufosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically confirmed, locally advanced or metastatic solid&#xD;
             malignancy; previously treated with at least one chemotherapy regimen for advanced or&#xD;
             metastatic disease or no effective standard treatment is available OR&#xD;
&#xD;
          -  Metastatic and/or locally advanced, inoperable pancreatic adenocarcinoma proven either&#xD;
             by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)&#xD;
&#xD;
          -  Measurable or nonmeasurable disease by RECIST criteria (at least one target or&#xD;
             nontarget lesion)&#xD;
&#xD;
          -  Recovered from reversible toxicities of prior therapy&#xD;
&#xD;
          -  Karnofsky performance status ≥70&#xD;
&#xD;
          -  Women of childbearing potential and men to use effective means of contraception from&#xD;
             entry into the study through 6 months after the last dose&#xD;
&#xD;
          -  Ability to understand the purposes and risks of the study and provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for metastatic/locally advanced pancreatic cancer&#xD;
&#xD;
          -  Prior administration of gemcitabine&#xD;
&#xD;
          -  Radiation therapy within 28 days prior to study start&#xD;
&#xD;
          -  Hormonal therapy, biologic therapy, chemotherapy or other systemic anti-tumor therapy&#xD;
             for cancer within 21 days prior to study start&#xD;
&#xD;
          -  Symptomatic brain metastases (baseline CT scan is not required in asymptomatic&#xD;
             subjects)&#xD;
&#xD;
          -  Active, clinically significant infection requiring antibiotics&#xD;
&#xD;
          -  Known HIV positive or active hepatitis B or C&#xD;
&#xD;
          -  History or symptoms of cardiovascular disease (NYHA Class 3 or 4)&#xD;
&#xD;
          -  Other primary malignancies (other than treated non-melanoma skin cancer or treated in&#xD;
             situ cancer) within the past 5 years&#xD;
&#xD;
          -  Major surgery within 3 weeks of the start of study treatment, without complete&#xD;
             recovery&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory test results (including complete&#xD;
             blood count, chemistry panel including electrolytes, and urinalysis)&#xD;
&#xD;
               -  Hemoglobin &lt;9 g/dL (may receive transfusion or erythropoietin to maintain),&#xD;
&#xD;
               -  ANC &lt;1500/μL,&#xD;
&#xD;
               -  Platelet count &lt;100,000/μL,&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 ×ULN,&#xD;
&#xD;
               -  AST/ALT &gt; 2.5-fold above ULN (&gt;5-fold above ULN if liver metastases),&#xD;
&#xD;
               -  Serum creatinine &gt; 2 mg/dL,&#xD;
&#xD;
               -  Creatinine clearance &lt; 60 mL/min (calculated)&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 28 days of the first&#xD;
             day of dosing on this study&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with the conduct of the study&#xD;
&#xD;
          -  Unwillingness or inability to comply with the study protocol for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Doenças Cardiovasculares - Biocor</name>
      <address>
        <city>Nova Lima</city>
        <state>BH</state>
        <zip>34000-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mãe de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceição</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII - Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo - Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>February 1, 2005</study_first_submitted>
  <study_first_submitted_qc>February 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2005</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2009</last_update_posted>
  <keyword>Pancreas</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Glufosfamide</keyword>
  <keyword>Advanced</keyword>
  <keyword>Solid</keyword>
  <keyword>Tumor</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Pancreatic Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

